Boston, MA -- (SBWIRE) -- 11/22/2013 -- GlobalData has released its new PharmaPoint Drug Evaluation report, “Razadyne/Reminyl (Alzheimer’s Disease) - Forecast and Market Analysis to 2022”. There are no long-term effective therapies for Alzheimer’s Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic therapies are relatively safe and effective, these therapies are still lacking because of they cannot maintain their effects and lack mechanisms that alter the course of the disease.

Razadyne (also known as Reminyl) is a reversible, competitive AChEI indicated for the treatment of mild to moderate AD. The exact MOA of galantamine is not known; however, it is thought to exert its effects by enhancing cholinergic function as a result of an increase in the concentration of ACh through reversible inhibition of hydrolysis by cholinesterase.

View Full Report Details and Table of Contents

Scope

- Overview of AD, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Razadyne / Reminyl including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Razadyne / Reminyl for the top eight countries from 2012 to 2022.
- Sales information covered for France, Germany, Italy, Spain, the UK, Japan, China and India.

Reasons to Get This Report

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for AD
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Razadyne / Reminyl performance
- Obtain sales forecast for Razadyne / Reminyl from 2012-2022 in top eight countries (France, Germany, Italy, Spain, the UK, Japan, China and India)

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- TRx0237 (Alzheimer’s Disease) - Forecast and Market Analysis to 2022
- MK-8931(Alzheimer’s Disease) - Forecast and Market Analysis to 2022
- EVP-6124 (Alzheimer’s Disease) - Forecast and Market Analysis to 2022
- Arimenda (Alzheimer’s Disease) - Forecast and Market Analysis to 2022
- Gantenerumab (Alzheimer’s Disease) - Forecast and Market Analysis to 2022
- Lu AE58054 (Alzheimer’s Disease) - Forecast and Market Analysis to 2022
- Crenezumab (Alzheimer’s Disease) - Forecast and Market Analysis to 2022
- Solanezumab (Alzheimer’s Disease) - Forecast and Market Analysis to 2022
- Namenda XR (Alzheimer’s Disease) - Forecast and Market Analysis to 2022
- Aricept (Alzheimer’s Disease) - Forecast and Market Analysis to 2022